|
Market Closed -
OTC Markets
21:57:28 21/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 48.00 USD | -2.04% |
|
0.00% | +20.00% |
| Market Cap | 56.94M 51.09M 47.24M 42.78M 79.92M 5.42B 80.89M 565M 225M 2.84B 214M 209M 9.01B | P/E 2024 |
225x | P/E 2025 | 8.64x |
|---|---|---|---|---|---|
| Enterprise Value | 64.56M 57.92M 53.55M 48.5M 90.61M 6.15B 91.71M 640M 255M 3.22B 242M 237M 10.21B | EV / Sales 2024 |
0.46x | EV / Sales 2025 | 0.24x |
| Free-Float |
17.04% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -2.04% | ||
| 3 months | -17.24% | ||
| 6 months | -7.21% | ||
| Current year | +20.00% |
| 1 month | 45 | 51.1 | |
| Current year | 37 | 58 | |
| 1 year | 21 | 58 | |
| 3 years | 21 | 58 | |
| 5 years | 15.51 | 62 | |
| 10 years | 4.01 | 62 |
| Manager | Title | Age | Since |
|---|---|---|---|
Darren Seirer
CEO | Chief Executive Officer | 52 | 01/01/2023 |
Nathan Shandy
DFI | Director of Finance/CFO | 39 | 02/08/2025 |
| Chief Executive Officer | 52 | 11/09/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 77 | 18/11/2015 | |
John Gonzalez
BRD | Director/Board Member | 76 | 01/06/2016 |
Gregory Melsen
BRD | Director/Board Member | 74 | 02/01/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/1/26 A | Free | Director | 2,500 | 0.2108% | ||
| 10/1/26 A | Free | Director | 2,500 | 0.2108% | ||
| 10/1/26 A | Free | Director | 2,500 | 0.2108% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.04% | 0.00% | +33.30% | +88.24% | 56.94M | ||
| +0.50% | +1.38% | +57.09% | +129.96% | 1,143B | ||
| +0.86% | +5.14% | +45.00% | +86.15% | 647B | ||
| -0.14% | +0.42% | +25.69% | +105.85% | 506B | ||
| -0.05% | +1.73% | +52.74% | +67.74% | 384B | ||
| -0.63% | -5.97% | +61.93% | +37.06% | 350B | ||
| +0.34% | +1.84% | +30.70% | +54.27% | 293B | ||
| -0.45% | +1.19% | +2.89% | +26.08% | 265B | ||
| +0.87% | +3.08% | +54.69% | +72.74% | 242B | ||
| +0.08% | +3.67% | +35.05% | +107.78% | 197B | ||
| Average | -0.07% | +1.30% | +39.91% | +77.59% | 402.76B | |
| Weighted average by Cap. | +0.25% | +1.55% | +44.50% | +89.02% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 183M 164M 152M 138M 257M 17.45B 260M 1.82B 724M 9.13B 687M 673M 28.98B | 207M 186M 172M 156M 291M 19.76B 295M 2.06B 819M 10.34B 778M 762M 32.82B |
| Net income | 551K 494K 457K 414K 773K 52.48M 783K 5.46M 2.18M 27.46M 2.07M 2.02M 87.18M | 5.66M 5.08M 4.69M 4.25M 7.94M 539M 8.04M 56.1M 22.35M 282M 21.23M 20.78M 895M |
| Net Debt | 36.99M 33.19M 30.68M 27.79M 51.91M 3.52B 52.54M 367M 146M 1.84B 139M 136M 5.85B | 7.62M 6.83M 6.32M 5.72M 10.69M 725M 10.82M 75.53M 30.09M 380M 28.58M 27.98M 1.2B |
Employees
353
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/10/26 | $48.00 | -2.04% | 100 |
- Stock Market
- Stocks
- JANL Stock
Select your edition
All financial news and data tailored to specific country editions
















